SunTrust initiated protection on Biogen and Amgen on Tuesday, ranking every inventory as a purchase based mostly on strong drug pipelines and progr
SunTrust initiated protection on Biogen and Amgen on Tuesday, ranking every inventory as a purchase based mostly on strong drug pipelines and progress alternatives in China.
SunTrust’s bullish thesis on Biogen is predicated on the corporate’s Alzheimer’s drug aducanumab. In October the company said it was once again seeking regulatory approval for the drug, which might be the primary of its sort within the billion-dollar Alzheimer’s market.
SunTrust additionally factors to Biogen’s energy in biosimilars, that are generic variations of biologic medicines used to deal with sicknesses like most cancers and autoimmune illnesses, in addition to progress alternatives in China.